BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34931867)

  • 41. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
    Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1).
    Shi X; Teng F
    Mol Cell Biochem; 2015 Oct; 408(1-2):283-93. PubMed ID: 26160280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
    Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ.
    Jiang X; Wu J; Zhang Y; Wang S; Yu X; Li R; Huang X
    Gene; 2018 Jun; 659():168-174. PubMed ID: 29551505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNA-145 inhibits proliferation and promotes apoptosis of HepG2 cells by targeting ROCK1 through the ROCK1/NF-κB signaling pathway.
    Wang RK; Shao XM; Yang JP; Yan HL; Shao Y
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2777-2785. PubMed ID: 31002128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.
    Yu D; Green B; Marrone A; Guo Y; Kadlubar S; Lin D; Fuscoe J; Pogribny I; Ning B
    Sci Rep; 2015 Feb; 5():8534. PubMed ID: 25704921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients.
    Wang C; Song B; Song W; Liu J; Sun A; Wu D; Yu H; Lian J; Chen L; Han J
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1630-7. PubMed ID: 21557766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
    Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
    Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MiR-490-5p inhibits the stemness of hepatocellular carcinoma cells by targeting ECT2.
    Yu Y; Cai O; Wu P; Tan S
    J Cell Biochem; 2019 Jan; 120(1):967-976. PubMed ID: 30206962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p.
    Wang ZY; Zhu Z; Wang HF; Qin B; Liu J; Yao XH; Li WC; Chen KS
    J Cell Physiol; 2019 Aug; 234(10):17775-17785. PubMed ID: 30864145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC.
    Zhao N; Sun H; Sun B; Zhu D; Zhao X; Wang Y; Gu Q; Dong X; Liu F; Zhang Y; Li X
    Sci Rep; 2016 Mar; 6():23091. PubMed ID: 26980408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma.
    Zhang T; Liu W; Zeng XC; Jiang N; Fu BS; Guo Y; Yi HM; Li H; Zhang Q; Chen WJ; Chen GH
    Biomed Pharmacother; 2016 Dec; 84():583-591. PubMed ID: 27694002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
    J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. miR-664b-5p Inhibits Hepatocellular Cancer Cell Proliferation Through Targeting Oncogene AKT2.
    Li H; Guo D; Zhang Y; Yang S; Zhang R
    Cancer Biother Radiopharm; 2020 Oct; 35(8):605-614. PubMed ID: 31967930
    [No Abstract]   [Full Text] [Related]  

  • 56. miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA.
    Cui W; Li Y; Xu K; Chen G; Lu X; Duan Q; Kang Z
    Biochem Biophys Res Commun; 2016 Oct; 479(4):901-906. PubMed ID: 27641667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.
    Yu G; Chen X; Chen S; Ye W; Hou K; Liang M
    J Transl Med; 2016 May; 14(1):122. PubMed ID: 27150195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-493 suppresses hepatocellular carcinoma tumorigenesis through down-regulation of anthrax toxin receptor 1 (ANTXR1) and R-Spondin 2 (RSPO2).
    Xu Y; Ge K; Lu J; Huang J; Wei W; Huang Q
    Biomed Pharmacother; 2017 Sep; 93():334-343. PubMed ID: 28651234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR.
    Wang Y; Cui M; Sun BD; Liu FB; Zhang XD; Ye LH
    Acta Pharmacol Sin; 2014 Sep; 35(9):1207-14. PubMed ID: 25087998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.